News & Views

  • New Chairman to Help Speed Products to Market
    L-R Emma Nolan, Dr Marco Giardiello, Dr Lee Tatham, Antony Odell, Professor Steve Rannard and Professor Andrew Owen

New Chairman to Help Speed Products to Market

Aug 19 2019 Read 453 Times

Tandem Nano Ltd, a University of Liverpool spin-out has appointed Antony Odell as Executive Chairman to accelerate the commercialisation of its proprietary technology to reformulate poorly soluble pharmaceuticals and chemicals. Antony has a significant track record in building successful life science businesses from early to late stage. Most recently Antony was CEO at Tissue Regenix Group plc which he led from laboratory proof of concept work to an Alternative Investment Market (AIM) listed business with significant overseas operations.

The University technology, which has been licensed into Tandem, has significant implications for optimisation of product manufacture across a broad range of market sectors from new therapy generation to novel agrochemical formulations, providing partners with tailored nanoparticles of insoluble materials. It is a result of collaboration between the research groups of Professor Andrew Owen, Department of Molecular and Clinical Pharmacology and Professor Steve Rannard, Department of Chemistry. Both Andrew and Steve are directors of the company.

Antony Odell said: “I’m delighted that Tandem has made this important first step in the commercialisation of its proprietary SDN technology which already has a significant track record of success in solving the problems of poorly soluble actives. The team at the University has developed several key commercial relationships that can now be developed further within the new company in a variety of sectors some of which have significant impact for Tandem’s strong corporate social responsibility ethic.”

Professor Andrew Owen, Academic Founder, said: “The spin-out of Tandem Nano Ltd is a resounding endorsement of the University’s cross-faculty activity that has seen new medicines transition from concept through preclinical selection, regulatory approval and first-in-human evaluation. The team will continue to drive development and understanding of new modalities to bring novel therapeutic options to patients that need them across the globe.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

Labmate UK & Ireland September 2019

September 2019

Articles Finding an easy, cost-effective way to break into new markets Exploring safe and intelligent multi-application liquid nitrogen cooling via auto-fill technology Characterisation o...

View all digital editions


Analytica Anacon India & IndiaLabExpo

Sep 19 2019 Hyderabad, India

16th Confocal Raman Imaging Symposium

Sep 23 2019 Ulm Germany

Analitica Latin America

Sep 24 2019 Sao Paulo, Brazil

Pharma Asia

Sep 24 2019 Karachi, Pakistan


Sep 24 2019 Basel, Switzerland

View all events